Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
NCT00140075
Completed
The purpose of this study is to compare two combinations of drugs, epirubicin given with a taxane (ET) or epirubicin given with cyclophosphamide (cytoxan) and followed by a taxane to see if one of the combinations is better at preventing or delaying the time for breast cancer recurrence and death after 3 years. The study will also evaluate the side effects of both treatment combinations.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/24/2011
Locations: Pfizer Investigational Site, Milwaukee, Wisconsin
Conditions: Adenocarcinoma
Register for Updates
Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma
NCT00003187
Completed
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Eliminating the T cells from the donor cells before transplanting them may prevent this from happening. PURPOSE: Randomized phase II/III trial to compare the effectiveness of conventional bone marrow transplantation with T cell-deple... Read More
Gender:
ALL
Ages:
55 years and below
Trial Updated:
02/23/2010
Locations: Midwest Children's Cancer Center, Milwaukee, Wisconsin
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Register for Updates
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
NCT00002707
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy using doxorubicin and cyclophosphamide with or without docetaxel in treating women who have stage II or stage III breast cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/02/2010
Locations: St. Vincent Hospital, Green Bay, Wisconsin +3 locations
Conditions: Breast Cancer
Register for Updates
Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus
NCT00017641
Unknown
OBJECTIVES: I. Determine the safety of immune ablation with high-dose cyclophosphamide and anti-thymocyte globulin followed by peripheral blood stem cell support in patients with systemic lupus erythematosus.
Gender:
ALL
Ages:
Between 0 years and 59 years
Trial Updated:
06/23/2005
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Systemic Lupus Erythematosus
Register for Updates